指南与共识消化、代谢与肾脏急症

非重症监护环境中195种药物肾毒性潜力的专家共识:改良德尔菲法

Expert Consensus on the Nephrotoxic Potential of 195 Medications in the Non-intensive Care Setting: A Modified Delphi Method.
指南 / 共识 · Drug Saf · 2023-05-24
一句话结论29名肾病或药学专家经改良德尔菲法对非重症监护环境195种药物肾毒性潜力达成共识,为未来临床评估和研究提供同质性基础。

该研究旨在为非重症监护患者建立标准化肾毒性药物监测清单及其肾毒性潜力(NxP)。通过全面文献检索识别潜在肾毒性药物,由29名具有肾病学或药学专长的参与者进行改良德尔菲法评级,每轮对每种药物按0-3分(无肾毒性至明确肾毒性)评分,若≥75%的回复为单一评分或两个连续评分的组合则达成组共识;若≥50%的回复为“未知”或“在非重症监护环境中未使用”则将该药物移除。共识别191种药物,第一轮后根据参与者建议新增4种,最终195种药物经三轮达成NxP指数评级共识:14种(7.2%)几乎在所有情况下无肾毒性(评分0);62种(31.8%)不太可能/可能肾毒性(评分0.5);21种(10.8%)可能肾毒性(评分1);49种(25.1%)可能/很可能肾毒性(评分1.5);2种(1.0%)很可能肾毒性(评分2);8种(4.1%)很可能/明确肾毒性(评分2.5);0种(0.0%)明确肾毒性(评分3);39种(20.0%)药物被移除考虑。作者认为NxP指数评级为非重症监护环境中感知的肾毒性药物提供了临床共识,并为未来临床评估和研究提供了同质性。

要点

  • 29名肾病或药学专家经改良德尔菲法对非重症监护环境195种药物进行肾毒性潜力评级,三轮后达成共识。
  • 共识评级分布:14种(7.2%)评分0;62种(31.8%)评分0.5;21种(10.8%)评分1;49种(25.1%)评分1.5;2种(1.0%)评分2;8种(4.1%)评分2.5;0种(0.0%)评分3。
  • 39种(20.0%)药物因≥50%回复为“未知”或“非重症监护环境未使用”而被移除考虑。
  • 组共识标准为≥75%的回复为单一评分或两个连续评分的组合。
  • NxP指数评级为未来临床评估和研究提供同质性,作者认为可用于非重症监护环境中肾毒性药物的临床共识。

适用人群与场景

  • 非重症监护环境(non-intensive care setting)中的患者。

诊断标准与关键阈值

  • 肾毒性潜力(NxP)评级采用0-3分制:0=无肾毒性,3=明确肾毒性。
  • 组共识标准:≥75%的回复为单一评分或两个连续评分的组合。
  • 移除标准:若≥50%的回复为“未知”或“在非重症监护环境中未使用”,则该药物被移除考虑。

研究设计与关键结果

  • 研究类型:改良德尔菲法专家共识。
  • 参与者:29名具有肾病学或药学专长的参与者。
  • 药物数量:文献检索识别191种药物,第一轮后根据参与者建议新增4种,共195种。
  • 三轮后NxP指数评级共识:14种(7.2%)评分0;62种(31.8%)评分0.5;21种(10.8%)评分1;49种(25.1%)评分1.5;2种(1.0%)评分2;8种(4.1%)评分2.5;0种(0.0%)评分3;39种(20.0%)药物被移除考虑。

证据类型、等级与局限

  • 证据类型:专家共识(改良德尔菲法)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为NxP指数评级为非重症监护环境中感知的肾毒性药物提供了临床共识,并为未来临床评估和研究提供了同质性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Nephrotoxin exposure is significantly associated with acute kidney injury (AKI) development. A standardized list of nephrotoxic medications to surveil and their perceived nephrotoxic potential (NxP) does not exist for non-critically ill patients.

OBJECTIVE: This study generated consensus on the nephrotoxic effect of 195 medications used in the non-intensive care setting.

METHODS: Potentially nephrotoxic medications were identified through a comprehensive literature search, and 29 participants with nephrology or pharmacist expertise were identified. The primary outcome was NxP by consensus. Participants rated each drug on a scale of 0-3 (not nephrotoxic to definite nephrotoxicity). Group consensus was met if ≥ 75% of responses were one single rating or a combination of two consecutive ratings. If ≥ 50% of responses indicated "unknown" or not used in the non-intensive care setting, the medication was removed for consideration. Medications not meeting consensus for a given round were included in the subsequent round(s).

RESULTS: A total of 191 medications were identified in the literature, with 4 medications added after the first round from participants' recommendations. NxP index rating consensus after three rounds was: 14 (7.2%) no NxP in almost all situations (rating 0); 62 (31.8%) unlikely/possibly nephrotoxic (rating 0.5); 21 (10.8%) possibly nephrotoxic (rating 1); 49 (25.1%) possibly/probably nephrotoxic (rating 1.5); 2 (1.0%) probably nephrotoxic (rating 2); 8 (4.1%) probably/definite nephrotoxic (rating 2.5); 0 (0.0%) definitely nephrotoxic (rating 3); and 39 (20.0%) medications were removed from consideration.

CONCLUSIONS: NxP index rating provides clinical consensus on perceived nephrotoxic medications in the non-intensive care setting and homogeneity for future clinical evaluations and research.

来源:Drug Saf,查看原文。版权归原作者所有。

参考来源

  1. Stottlemyer BA, Abebe KZ, Palevsky PM, et al. Expert Consensus on the Nephrotoxic Potential of 195 Medications in the Non-intensive Care Setting: A Modified Delphi Method. Drug Saf. 2023. PMID: 37223847. doi:10.1007/s40264-023-01312-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。